Refludan Coronary Syndrome Use Not Supported By Heparin-Placebo Data
Executive Summary
Aventis was unable to convince FDA and its Cardiovascular & Renal Drugs Advisory Committee that its thrombin inhibitor Refludan is superior to placebo in the treatment of acute coronary syndromes by inference from historical data comparing heparin and placebo.